LogoFDA 510(k) Search
Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K030178

    Validate with FDA (Live)

    Device Name
    CALCIGEN PSI BONE GRAFT SUBSTITUTE
    Manufacturer
    BIOMET, INC.
    Date Cleared
    2003-02-26

    (40 days)

    Product Code
    MQV
    Regulation Number
    888.3045
    Type
    Traditional
    Panel
    Orthopedic
    Reference & Predicate Devices
    K020986,K013072,K011531,K013960,K013966,K014156,K014053,K011048,K994337,K990131
    Predicate For
    K032286,K050490
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    Calcigen™ PSI bone graft substitute is indicated for bony voids or gaps of the skeletal system (i.e., the extremities, spine and pelvis) that are not intrinsic to the stability of the bony structure. These defects may be surgically created osseous defects or osseous defects created from disease or traumatic injury to the bone. Calcigen™ PSI resorbs and is replaced with bone during the healing process.

    Device Description

    Calcigen™ PSI bone graft substitute is a resorbable osteoconductive scaffold composed of 60% hydroxyapatite (HA) and 40% tri-calcium phosphate (TCP). The device is available as granules, cubes, or cylinders. Calcigen™ PSI is porous with multidirectional interconnected pores resembling that of cancellous bone. Calcigen™ PSI is supplied sterile for single patient, one time use only.

    AI/ML Overview

    I am sorry, but the provided text does not contain any information about acceptance criteria or a study proving that a device meets those criteria. The document is a 510(k) summary and an FDA clearance letter for a bone graft substitute called Calcigen™ PSI.

    It describes:

    • The device (Calcigen™ PSI bone graft substitute)
    • Its intended use (filling bony voids or gaps)
    • Its composition (60% hydroxyapatite (HA) and 40% tri-calcium phosphate (TCP))
    • Its substantial equivalence to other legally marketed predicate devices.

    The FDA clearance is based on the device being "substantially equivalent" to predicate devices, implying similar performance and safety characteristics. However, there are no specific numerical acceptance criteria or a study with performance metrics presented in this document. The clearance letter confirms that the device can be marketed based on this substantial equivalence determination, not based on meeting specific, predefined performance criteria from a clinical or analytical study.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1